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ABSTRACT: O-GlcNAc transferase (OGT) is an essential glycosyl-
transferase that installs the O-GlcNAc post-translational modiﬁcation
on the nucleocytoplasmic proteome. We report the development of S-
linked UDP−peptide conjugates as potent bisubstrate OGT
inhibitors. These compounds were assembled in a modular fashion
by photoinitiated thiol−ene conjugation of allyl-UDP and optimal
acceptor peptides in which the acceptor serine was replaced with
cysteine. The conjugate VTPVC(S-propyl-UDP)TA (Ki = 1.3 μM)
inhibits the OGT activity in HeLa cell lysates. Linear fusions of this
conjugate with cell penetrating peptides were explored as prototypes
of cell-penetrant OGT inhibitors. A crystal structure of human OGT
with the inhibitor revealed mimicry of the interactions seen in the
pseudo-Michaelis complex. Furthermore, a ﬂuorophore-tagged derivative of the inhibitor works as a high aﬃnity probe in a
ﬂuorescence polarimetry hOGT assay.
The reversible attachment of β-N-acetylglucosamine (O-GlcNAc) to serine and threonine residues of nucleocy-
toplasmic proteins is a highly conserved and dynamic post-
translational modiﬁcation (PTM) found in higher eukaryotes.1,2
The transfer of O-GlcNAc from the donor substrate UDP-
GlcNAc onto substrate proteins is catalyzed by the O-GlcNAc
transferase (OGT), while the removal is catalyzed by the O-
GlcNAc hydrolase (OGA).3 Both enzymes possess substantial
substrate promiscuity, which enables this single pair of enzymes
to control the O-GlcNAc proteome linked to the regulation of
a range of cellular processes.4,5 Protein O-GlcNAcylation is
essential for proper development of the animal embryo,6−8 and
mutations in the O-GlcNAc transferase have recently been
associated with intellectual disability.9−11 Multiple metabolic
pathologies, such as diabetes12,13 and cancer,14−16 as well as
neurological diseases17,18 such as Alzheimer’s and Parkinson’s
have been linked to dysregulation of protein O-GlcNAcylation.
Elucidation of the precise biological role(s) of protein O-
GlcNAcylation is markedly hampered by the lack of potent and
selective inhibitors of OGT.19 The unusual catalytic machinery
of the enzyme, which only seems to be fully assembled on the
binding of the donor substrate,20 has proven to be diﬃcult to
target. Previously, high-throughput compound screening
studies have yielded cell penetrant small molecules like
BZX21,22 and OSMI1.23 The former renders OGT inactive by
cross-linking Lys842 and Cys917 in the active site. Given its
reactivity, BZX may also target enzymes that contain similar
Lys/Cys pairs. OSMI1 inhibits OGT through an as of yet
unknown mechanism and was also shown to aﬀect cell surface
glycosylation.23 The most widely used OGT inhibitor, the per-
acetylated derivative of 5-thio-N-acetylglucosamine, hijacks the
hexosamine biosynthetic pathway to yield the donor substrate
analogue UDP-5S-GlcNAc that is inherently nonselective in the
context of several other families of essential UDP-GlcNAc
processing glycosyl transferases present in the cell.24
Recently, we have reported the synthesis and kinetic
evaluation of bisubstrate OGT inhibitors that have been
conceived by tethering the anchoring UDP moiety of the donor
substrate to the serine side chain of a series of heptapeptides
derived from several human OGT (hOGT) acceptor
proteins.25 The bisubstrate UDP−peptide conjugate VTPVS-
(O-propyl-UDP)TA 1 acted as a competitive hOGT inhibitor
in vitro (IC50 = 18 μM
25).
To develop these UDP−peptide conjugates into useful
chemical biology tools two problems need to be addressed.
First, the potency needs to be increased to eﬀectively compete
with the donor substrate UDP-GlcNAc (Kd = 16 μM
20).
Second, the intrinsic cell penetrance of these conjugates is
limited by their size and the negative charge of the UDP
moiety. To address the ﬁrst problem, an expedient access to a
diverse set of bisubstrate inhibitors was required to enable
eﬃcient structure−activity studies. To improve cell penetrance,
we aimed to fuse the bisubstrate “warhead” to a selection of cell
penetrating peptides (CPP) to achieve cellular uptake.
In our original approach, the phosphorylated “stretched
serine” building block was incorporated into the backbone of a
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peptide with subsequent formation of the pyrophosphate bond
in a reaction with an activated UMP derivative (Figure 1). To
improve synthetic eﬃciency we sought an alternative modular
strategy that would enable installation of tethered UDP as the
single moiety on a variety of peptide backbones. Advanta-
geously, the suggested convergent approach would also
facilitate the assembly of the proposed CPP-bisubstrate
inhibitors by solid phase peptide synthesis (SPPS) followed
by attachment of the tethered UDP as the last synthetic step.
As the chemical structure of the O-linked UDP−peptide
conjugates showed limited opportunity for modular assembly,
we instead opted to explore novel S-linked UDP−peptide
conjugates that could be accessed by chemoselective cysteine
modiﬁcation with a thiol-reactive tethered UDP derivative
(Figure 2). Evaluation of three mainstay techniques for
carbon−sulfur bond formation such as Michael addition
(Path A), phosphine promoted disulﬁde contraction26 (Path
B), and “click” thiol−ene conjugation (TEC)27−30 (Path C) in
the context of construction of such thiol reactive UDP
derivatives revealed inherent limitations of the ﬁrst two
approaches (Figure 2). Indeed, introduction of a mandatory
electron withdrawing group would disrupt the topological
integrity of the linker in the proposed Michael type reactive
derivative. In turn, disulﬁde contraction, widely used for
preparation of S-linked glycoproteins, seemed to be less
attractive for peptide substrates, as it would unavoidably result
in the loss of the stereochemical integrity of the linking
cysteine. In fact, only photoinitiated TEC reaction of cysteine
containing peptides with simplistic allyl-UDP 4 held promise
for an eﬃcient assembly of the envisaged conjugates.
To synthesize the requisite allyl-UDP 4 the Bogachev−
Kiessling31,32 protocol was used by coupling UMP N-methyl
imidazolide 3 with the crude bis-triethylammonium salt of allyl
phosphoric acid, prepared in turn from allyl bis-ﬂuorenemethyl
phosphate 2 (Scheme 1, Scheme S8).
The structure of 4 was unambiguously assigned by a set of
spectroscopic methods (Figures S1−S3); the presence of a
pyrophosphate bond was conﬁrmed by a typical pair of
doublets (σ −11, −12, JP,P = 21 Hz) in the 31P NMR spectrum.
The photoinitiated TEC reaction between 4 and 20% molar
excess of the substrate peptide VTPVCTA 5 was initially
attempted at 10 mM in 0.1 M acetate buﬀer (pH 4) in the
presence of 20% of diﬀerent water-soluble photoinitiators VA-
044, DMPA (50% MeOH additive), or LAP.33 The reactions
were irradiated using an 8 W Camag TLC reader lamp at 366
nm and monitored by LC-MS. We found that LAP eﬃciently
mediated the conjugation, resulting in clean formation of the
expected product 6 (m/z 1175) after only 10 min (Scheme
2A).
On the other hand, <5% conversion was detected with VA-
044, while no reaction took place with DMPA. The TEC
reaction was equally eﬃcient when no excess of the substrate
peptide was present and with only 10% of the photoinitiator.
No products were observed in the absence of LAP or without
UV light. The reaction was scaled up to 0.05 mmol (20 mM in
water), and the S-linked UDP−peptide conjugate 6 was
isolated by preparative HPLC in 56% yield. The structure of
the product was veriﬁed by 1H and 13C NMR spectra, proving
the presence of the peptide backbone and the UDP moiety
(Figures S4, S5). The 31P spectrum showed two broadened
Figure 1. Synthesis and structure of the O-linked UDP−peptide conjugate 1.25
Figure 2. Selected possible approaches to the synthesis of S-linked
UDP−peptide conjugates. In path A an electron withdrawing group in
the Michael acceptor would disrupt the topological integrity of the
linker. Path B leads to isomerization at Cys.26 Path C allows for the
eﬃcient construction of the target molecule.
Scheme 1. Chemical Synthesis of Allyl-UDPa
a(i) Et3N-DCM, 4:1, 16 h; (ii) a) Bogachev−Kiessling coupling, 3 h; b) MeOH, Et3N, H2O, 16 h, 44%.
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singlets at σ −10.94 and −11.48, conﬁrming the integrity of the
pyrophosphate bond.
The inhibitory potency of 6 was assessed by the previously
described ﬂuorometric OGT activity assay.25 Unexpectedly, the
S-linked UDP peptide conjugate 6 appeared to be an almost
10-fold more potent hOGT inhibitor (IC50 = 2 μM) than its O-
linked progenitor 125 (Figure 3A). To provide a negative
control and on the assumption that hOGT evolved to bind D-
conﬁgured UDP, we synthesized the L-uridine congener 7
starting from allyl-L-UDP 4-L (Scheme 2A, Scheme S10),
which showed no inhibition of hOGT (Figure 3A). Next, we
demonstrated that 6 is also a hOGT inhibitor in a cell-free
system, reducing protein O-GlcNAcylation in a dose-dependent
manner by about 50% at 1 mM (Figure 3B, Figure S6).
Next, we attempted the assembly of the potentially cell
penetrating bisubstrate hOGT inhibitors. To this end, starting
from peptides featuring a VTPVCTA C-terminus and either
Penetratin (RQIKIWFQNRRMKWKK - 8/9)34 or TAT
(YGRKKRRQRRR - 10)35 peptides at the N-terminus, we
synthesized S-linked UDP peptide conjugates 11−13 by TEC
reaction with allyl-UDP 4 (Scheme 2C).
Encouragingly, the conjugates 11 and 13 (IC50[13] = 5 μM,
Figure S7) were shown to be almost as potent hOGT inhibitors
in vitro as the parent compound 6. However, neither 11 nor 13
had a noticeable eﬀect on total O-GlcNAcylation in cell
cultures at concentrations up to 1 mM (Figure S8). Moreover,
microscopy of the HeLa cells treated with the 5-ﬂuorescein
thioureide (Flut) labeled conjugate 12 for 24 h revealed
ﬂuorescent puncta (Figure S8). Taken together, these data
suggest that while 12 and, implicitly 11 and 13, could cross the
cell membrane, they remain trapped in the early endo-
somes36,37 and therefore cannot target cytosolic hOGT.
Discovery of the potent hOGT binder 6 also oﬀers an
opportunity for development of a sensitive hOGT ﬂuorescence
polarimetry assay (FP). We explored the ﬂuorescently tagged
derivative 17 of the inhibitor as a high aﬃnity FP probe. To this
end, the peptide 14 was eﬃciently transformed into
corresponding S-linked UDP−peptide conjugate by TEC
reaction with allyl-UDP 4. Next, the N-terminal 6-amino-
hexanoyl (ahx) residue was tagged with 5(6)-ﬂuorescein NHS
ester to give the requisite 5(6)-ﬂuorescein carboxamide (Floc)
labeled derivative 17 (Scheme 2B). The same reaction
Scheme 2. Photoinitiated Thiol−Ene Conjugation of
Cysteine Containing Peptides with Allyl-UDPa
a(i) 8 W 366 nm, 10 min, 50−55%; (ii) 5(6)-ﬂuorescein NHS ester,
DMF, 0.15 M NaHCO3, 3 h, 85%.
Figure 3. (A) Dose−response curves of inhibition of hOGT activity in the presence of increasing concentrations of 6 and 7. Errors shown represent
the s.e.m. of three replicates. (B) Western blot analysis of cell lysate in the presence and absence of 6, 7, and UDP-5S-GlcNAc. HeLa cell lysates were
O-GlcNAc stripped by the potent bacterial O-GlcNAcase CpOGA, whose activity was then blocked by the potent OGA inhibitor GlcNAcstatin G.
These stripped lysates were then re-O-GlcNAcylated by recombinant OGT and blotted for protein O-GlcNAcylation using the RL2 antibody.
HSP60 was used as a loading control.
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sequence was performed with 14 and allyl-L-UDP 4-L to give
the negative control compound 18.
Direct binding aﬃnity of compound 17 to hOGT was
measured, yielding a KD of 1.6 μM, whereas no quantiﬁable
binding could be detected for the corresponding negative
control 18 (Figure 4A). The observed value is in good
agreement with the IC50 of 2 μM established in our activity
assay.
To verify whether the probe 17 could be used in a workable
FP hOGT assay we demonstrated that the available competitive
inhibitors UDP-5S-GlcNAc24 and 1 displace 17 from the
complex with the enzyme in a dose-dependent manner (Figure
4B). The derived values of Ki = 7 ± 2 μM (1) and Ki = 5 ± 2
μM (UDP-5S-GlcNAc) were in agreement with the previously
reported aﬃnities,20,25 validating this assay.
Next, we used this assay platform to examine the eﬀect of the
peptide sequence on the inhibitory potency of the S-linked
UDP−peptide conjugates. We compiled a set of peptides
derived from the known hOGT substrate proteins RB2, TAB1,
CK2, and KER, as well as a previously published hOGT
sequon38 (Table 1). The topology of the heptapeptides in the
7-S5C subseries (19−23) was chosen to replicate that of the
peptide 5. The nonapeptides 9-S5C (24−26) were designed
with a centrally located Cys. The pair of the tridecapeptides 27
and 28 was included to explore distant regions of the binding
groove. The TEC reaction of allyl-UDP 4 with all substrates
worked routinely well to give an array of the novel S-linked
UDP−peptide conjugates 29−38 (Table 1, Table S1) that were
evaluated by the modiﬁed FP assay (Table 1, Figure 5).
The collated data (Table 1) suggest that conjugates derived
from the heptapeptides 7-S5C cover the minimal structure of
the bisubstrate inhibitor until there is proline in the −2
position, as the binding potency remains in the range of 1 ± 0.5
μM (note the potency drop in the conjugate 29 (entry 2)).
These data, taken together, are in good agreement with
previous ﬁndings that emphasize the importance of a proline in
the −2 position.38 Notably, C-terminal elongation of conjugates
in 9-S5C and 13-SC3 series results in a steady potency drop,
while N-terminal extension did not aﬀect the binding of the 13-
S11C conjugate 38.
To reveal likely reasons for the enhanced potency of the S-
linked UDP−peptide conjugates we collected high-resolution
synchrotron diﬀraction data of crystals of hOGT in complex
with 6 (1.85 Å, Rwork/Rfree = 0.22/0.25) or its O-linked
progenitor 1 (1.68 Å, Rwork/Rfree = 0.19/0.22) (Figure 6, Table
S2). Structure solution by molecular replacement and
subsequent reﬁnement revealed continuous |Fo|−|Fc| electron
density for both ligands allowing the unambiguous placement
of each (Figure S9). The fully reﬁned models revealed both
conjugates bind to the OGT active site in a conformation
closely resembling the previously reported pseudo-Michaelis
Figure 4. (A) FP assay showing the binding of 17 and 18 to hOGT. (B) Dose−response curves from the FP assay showing the displacement of 17
by UDP-5S-GlcNAc, 1 and 6. Errors shown represent the s.e.m. of at least three replicates.
Table 1. Inhibition of hOGT with UDP−Peptide Bisubstrate Conjugates 6 and 29−38
sequence origin/Cys position Cys peptide product Ki (μM)
1 VTPVCTA RB2_7-S5C 5 6 1.3 ± 0.8
2 VPTVCTA pseudo RB2_7-S5C 19 29 12.8 ± 4.5
3 SVPYCSA TAB1_7-S5C 20 30 2.3 ± 1.6
4 VTPVCSA CK2_7-S5C 21 31 1.2 ± 1.3
5 VTPVCRA SEQ_7-S5C 22 32 1.3 ± 0.5
6 PVFTCRS KER_7-S5C 23 33 12.5 ± 7
7 VTPVCTATH RB2_9-S5C 24 34 12.7 ± 2.3
8 SVPYCSAQS TAB1_9-S5C 25 35 15 ± 2.3
9 PVFTCRSAA KER_9-S5C 26 36 56 ± 32
10 PVCTATHSLSRLH RB2_13-S3C 27 37 80 ± 46
11 KENSPAVTPVCTA RB2_13-S11C 28 38 1.8 ± 1.3
Figure 5. Schematic of the synthesis of UDP−peptide bisubstrate
conjugates shown in Table 1.
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complex of hOGT with UDP-5S-GlcNAc and an acceptor
peptide20 (Figure 6). The largest atomic shift between the UDP
moieties of conjugates 1 and 6 and the corresponding
substrates/substrate analogues is 0.7−0.8 Å. Shifts were also
observed between the positions of the linking oxygen and sulfur
(0.8 Å) and the positions of the linker C1 atoms (1.1 Å).
Overall, in the conjugate 1 the linker adopts a synclinal
conformation (dihedral angle O−C1−C2−C3 of 72°), while in
6 the linker adopts an antiperiplanar conformation (dihedral
angle S−C1−C2−C3 171.4°). This diﬀerence may contribute to
the increased potency of 6, as the antiperiplanar conformation
of the thio-propyl linker seen in 6 is energetically more
favorable than the synclinal conformation of the oxy-propyl
linker in 1.
In conclusion, we developed a modular synthetic approach to
S-linked UDP−peptide conjugates using a photoinitiated TEC
reaction between allyl-UDP and cysteine containing peptides. A
series of conjugates sharing the XXPXC(S-propyl-UDP)XX
scaﬀold showed binding potency toward hOGT in the 1 ± 0.5
μM range in vitro, which places them among the most potent
hOGT inhibitors reported to date. The increased potency of
the conjugate VTPVC(S-propyl-UDP)TA in comparison with
its O-linked progenitor correlates with the more relaxed
conformation of the thiopropyl linker. We have shown that
the chosen S-linked conjugate inhibits recombinant hOGT
activity in HeLa cell lysates and successfully assembled two
prototypes of the cell-penetrating bisubstrate hOGT inhibitors
that feature Penetratin and TAT peptides C-terminally
extended with the VPTVC(S-propyl-UDP)TA motif. Finally,
we developed a practical variant of the ﬂuorescence polarimetry
hOGT assay using a ﬂuorescently labeled derivative of the
bisubstrate conjugate as a high aﬃnity probe suitable for high-
throughput screening. Further optimization of the structure of
the novel hOGT bisubstrate inhibitors as well as evaluating of
diﬀerent types of cell penetrating vehicles could lead to further
improvements of this scaﬀold.
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